HRP20170514T4 - Epitopi sklerostina - Google Patents
Epitopi sklerostina Download PDFInfo
- Publication number
- HRP20170514T4 HRP20170514T4 HRP20170514TT HRP20170514T HRP20170514T4 HR P20170514 T4 HRP20170514 T4 HR P20170514T4 HR P20170514T T HRP20170514T T HR P20170514TT HR P20170514 T HRP20170514 T HR P20170514T HR P20170514 T4 HRP20170514 T4 HR P20170514T4
- Authority
- HR
- Croatia
- Prior art keywords
- monoclonal antibody
- seq
- fragment
- antibody according
- cdr
- Prior art date
Links
- 102000019307 Sclerostin Human genes 0.000 title claims 2
- 108050006698 Sclerostin Proteins 0.000 title claims 2
- 239000012634 fragment Substances 0.000 claims 7
- 210000000988 bone and bone Anatomy 0.000 claims 6
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102000058171 human SOST Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 230000035876 healing Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 102000016943 Muramidase Human genes 0.000 claims 1
- 108010014251 Muramidase Proteins 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000033558 biomineral tissue development Effects 0.000 claims 1
- 230000037118 bone strength Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960000274 lysozyme Drugs 0.000 claims 1
- 235000010335 lysozyme Nutrition 0.000 claims 1
- 239000004325 lysozyme Substances 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Claims (9)
1. Monoklonsko protutijelo koje se veže na dio ljudskog sklerostina i ima afinitet vezanja za ljudski sklerostin koji je manji od ili jednak 1 x 10-10 M, pri čemu se navedeni dio sastoji od aminokiselina 57-64, 73-86, 111-117 i 138-144 SEQ ID NO: 1 i ima sve tri od:
(a) disulfidne veze između aminokiselina 57 i 111;
(b) disulfidnu vezu između aminokiselina 82 i 142; i
(c) disulfidnu vezu između aminokiselina 86 i 144.
2. Monoklonsko protutijelo u skladu s patentnim zahtjevom 1 koje je fragment F(ab’)2, Fab, Fab’ ili Fv.
3. Monoklonsko protutijelo u skladu s patentnim zahtjevom 1 ili 2, koje je humanizirano protutijelo ili ljudsko protutijelo.
4. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 3, koje se veže za ljudski sklerostin s afinitetom vezanja koji je manji od ili jednak 1 x 10-11 M ili manji od ili jednak 1 x 10-12 M.
5. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 3, koje se veže za ljudski sklerostin s afinitetom koji je najmanje 50, 100, 250, 500, 1000 ili 10,000 puta veći od afiniteta za lizozim bjelanjka jajeta.
6. Monoklonsko protutijelo prema patentnom zahtjevu 1 koje sadrži sljedeće CDR odsječke:
CDR-L1 odsječka SEQ ID NO: 284
CDR-L2 odsječka SEQ ID NO: 285
CDR-L3 odsječka SEQ ID NO: 286
CDR-H1 odsječka SEQ ID NO: 296
CDR-H2 odsječka SEQ ID NO: 297
CDR-H3 odsječka SEQ ID NO: 298.
7. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 1 do 6, koje povećava najmanje jednu koštanu formaciju, mineralnu koštanu gustoću, sadržaj minerala u kosti, koštanu masu, kvalitetu kosti i čvrstinu kosti u sisavca ili koja blokira inhibitorni učinak sklerostina u testu mineralizacije koji se temelji na stanici.
8. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 1 do 7, koje se koristi za liječenje osteoporoze ili osteopenije.
9. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 1 do 7, koje se koristi u postupku poboljšanja ishoda kod ortopedskih zahvata, dentalnih zahvata, operacija usadka, zamjene zgloba, presađivanja kosti, kozmetičke operacije kosti i reparacije poput liječenja lomova, zacjeljivanja bez srastanja, zakašnjelog zacjeljivanja bez srastanja ili rekonstrukcije lica.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67758305P | 2005-05-03 | 2005-05-03 | |
| US77684706P | 2006-02-24 | 2006-02-24 | |
| US78224406P | 2006-03-13 | 2006-03-13 | |
| US79264506P | 2006-04-17 | 2006-04-17 | |
| US11/410,540 US8003108B2 (en) | 2005-05-03 | 2006-04-25 | Sclerostin epitopes |
| PCT/US2006/016345 WO2006119062A2 (en) | 2005-05-03 | 2006-04-28 | Sclerostin epitopes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20170514T1 HRP20170514T1 (hr) | 2017-06-02 |
| HRP20170514T4 true HRP20170514T4 (hr) | 2023-11-10 |
Family
ID=36956127
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170514TT HRP20170514T4 (hr) | 2005-05-03 | 2006-04-28 | Epitopi sklerostina |
| HRP20170679TT HRP20170679T4 (hr) | 2005-05-03 | 2006-04-28 | Epitopi sklerostina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170679TT HRP20170679T4 (hr) | 2005-05-03 | 2006-04-28 | Epitopi sklerostina |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8003108B2 (hr) |
| EP (6) | EP2295448B2 (hr) |
| JP (7) | JP5680823B2 (hr) |
| CA (1) | CA2607276C (hr) |
| CY (2) | CY1118977T1 (hr) |
| DK (2) | DK2251351T4 (hr) |
| ES (5) | ES2901698T3 (hr) |
| FI (2) | FI2251351T4 (hr) |
| HR (2) | HRP20170514T4 (hr) |
| HU (2) | HUE032092T2 (hr) |
| LT (2) | LT2301961T (hr) |
| MX (1) | MX348432B (hr) |
| MY (1) | MY174493A (hr) |
| PL (2) | PL2301961T5 (hr) |
| PT (2) | PT2251351T (hr) |
| SI (2) | SI2251351T2 (hr) |
| WO (1) | WO2006119062A2 (hr) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ512122A (en) | 1998-11-27 | 2003-12-19 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
| CN101500608A (zh) | 2006-06-08 | 2009-08-05 | 中外制药株式会社 | 炎性疾病的预防或治疗药 |
| US20100036091A1 (en) * | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| SI3345607T1 (sl) * | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
| WO2008101234A2 (en) * | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| CN101646457B (zh) | 2007-03-20 | 2013-05-01 | 伊莱利利公司 | 抗硬骨素抗体 |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| WO2009041613A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗体定常領域改変体 |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| EP2209491B1 (en) | 2007-11-02 | 2015-10-28 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
| ES2834741T3 (es) | 2007-12-05 | 2021-06-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-NR10 y uso del mismo |
| CA2708065C (en) | 2007-12-05 | 2015-02-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
| CN101896201A (zh) | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
| LT2708559T (lt) | 2008-04-11 | 2018-06-11 | Chugai Seiyaku Kabushiki Kaisha | Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių |
| AU2009288354A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗ｎｒ１０抗体、およびその利用 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | Antibody constant region change body |
| PL2896404T3 (pl) * | 2009-06-04 | 2017-12-29 | Novartis Ag | Sposoby identyfikacji miejsc koniugacji IgG |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| CN102711809B (zh) * | 2009-08-17 | 2015-09-30 | 特雷康制药公司 | 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症 |
| IN2012DN05101A (hr) * | 2010-01-19 | 2015-10-23 | Immunomedics Inc | |
| BR112012027994B1 (pt) | 2010-05-04 | 2021-10-13 | Five Prime Therapeutics, Inc | Anticorpo, composição farmacêutica e uso de um anticorpo |
| SG185465A1 (en) * | 2010-05-14 | 2012-12-28 | Amgen Inc | High concentration antibody formulations |
| KR20180019247A (ko) | 2010-11-05 | 2018-02-23 | 노파르티스 아게 | Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| EA201391248A1 (ru) * | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
| CR20160147A (es) * | 2011-03-25 | 2016-08-03 | Amgen Inc | Formulaciones de anticuerpos |
| DK2699261T3 (en) | 2011-04-19 | 2018-09-17 | Amgen Inc | Method of treating osteoporosis |
| US20140056912A1 (en) | 2011-04-29 | 2014-02-27 | Novartis Ag | Methods of treating squamous cell carcinoma |
| EP2739311B9 (en) | 2011-08-04 | 2018-09-19 | Amgen Inc. | Method for treating bone gap defects |
| KR20200056473A (ko) | 2011-12-28 | 2020-05-22 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| HUE043851T2 (hu) | 2013-02-22 | 2019-09-30 | Abbvie Stemcentrx Llc | Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk |
| JOP20140049B1 (ar) | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
| US10308721B2 (en) | 2014-02-21 | 2019-06-04 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
| KR20230086809A (ko) | 2014-06-23 | 2023-06-15 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법 |
| EA038462B1 (ru) | 2014-10-23 | 2021-08-31 | Эмджен Инк. | Снижение вязкости фармацевтических составов |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| JP2017537084A (ja) | 2014-11-12 | 2017-12-14 | トラコン ファーマシューティカルズ、インコーポレイテッド | 抗エンドグリン抗体及びその用途 |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| SG11201704792UA (en) | 2014-12-22 | 2017-07-28 | Five Prime Therapeutics Inc | Anti-csf1r antibodies for treating pvns |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| DK3269735T3 (da) * | 2015-03-13 | 2020-12-14 | Jiangsu Hengrui Medicine Co | Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| BR112017022101A2 (pt) | 2015-04-14 | 2018-07-31 | Chugai Seiyaku Kabushiki Kaisha | composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| CL2016000164A1 (es) * | 2016-01-21 | 2016-07-29 | Pontificia Universidad Católica De Chile | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv. |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| EA039540B1 (ru) * | 2016-03-25 | 2022-02-08 | Онкомед Фармасьютикалс, Инк. | Связывающие tigit агенты и варианты их применения |
| MY197836A (en) | 2016-07-12 | 2023-07-20 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| JP2019527710A (ja) | 2016-08-08 | 2019-10-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた結合組織付着の改善方法 |
| EP3548071A4 (en) | 2016-11-30 | 2020-07-15 | OncoMed Pharmaceuticals, Inc. | METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES |
| JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| CN110325548B (zh) | 2016-12-21 | 2023-11-17 | 美莱奥生物制药第三有限公司 | 抗硬化蛋白抗体在治疗成骨不全症中的用途 |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| US12103979B2 (en) | 2017-04-28 | 2024-10-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| KR102560646B1 (ko) | 2017-08-01 | 2023-07-27 | 암젠 인크 | 질량 분광분석법으로의 분석을 위한 폴리펩티드 샘플의 실시간 제조를 위한 시스템 및 방법 |
| CN110892267B (zh) | 2017-08-01 | 2024-08-09 | 安进公司 | 用于对样品进行实时聚糖测定的系统和方法 |
| JP2020535119A (ja) | 2017-09-13 | 2020-12-03 | ファイヴ プライム セラピューティクス インク | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法 |
| KR20200131266A (ko) | 2018-03-13 | 2020-11-23 | 암젠 인크 | 질량 분광 분석을 위한 폴리펩티드의 순차적 소화 |
| EP3765856B1 (en) | 2018-03-13 | 2023-09-27 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| CA3093457A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| US20210308265A1 (en) | 2018-08-10 | 2021-10-07 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
| CA3126018A1 (en) | 2018-12-14 | 2020-06-18 | Amgen Inc. | System suitability method for use with protein concentration determination by slope |
| US20220137061A1 (en) | 2019-02-14 | 2022-05-05 | Amgen Inc. | Systems And Methods For Preparing A Sample and Performing A Real-Time Assay Of The Sample |
| US20220137010A1 (en) | 2019-02-20 | 2022-05-05 | Amgen Inc. | Methods of determining protein stability |
| CA3130462A1 (en) | 2019-03-04 | 2020-09-10 | Amgen Inc. | In vivo reversibility of high molecular weight species |
| CA3133459A1 (en) | 2019-03-27 | 2020-10-01 | Amgen Inc. | Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products |
| US20220260584A1 (en) | 2019-06-05 | 2022-08-18 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
| MX2022001805A (es) | 2019-08-12 | 2022-06-08 | Amgen Inc | Formulaciones de anticuerpos anti-esclerostina. |
| WO2021030423A1 (en) * | 2019-08-13 | 2021-02-18 | The Feinstein Institutes For Medical Research | Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies |
| BR112022006590A2 (pt) | 2019-11-20 | 2022-06-28 | Chugai Pharmaceutical Co Ltd | Preparação contendo anticorpos |
| JP2023543167A (ja) | 2020-09-18 | 2023-10-13 | アムジエン・インコーポレーテツド | ペプチドマッピング分析のための試料を処理する方法 |
| CA3200262A1 (en) | 2020-11-05 | 2022-05-12 | Amgen Inc. | Materials and methods for protein processing |
| CA3237662A1 (en) | 2021-11-09 | 2023-05-19 | Amgen Inc. | Production of therapeutic proteins |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US32011A (en) | 1861-04-09 | Coffee-pot | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5837456A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| AU662304B2 (en) | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| AU700371B2 (en) | 1993-06-07 | 1999-01-07 | Genentech Inc. | Hiv envelope polypeptides |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5863738A (en) | 1994-04-29 | 1999-01-26 | Creative Biomolecules, Inc. | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| KR20000015893A (ko) | 1996-05-22 | 2000-03-15 | 댄 마이클 | 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도 |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| EP1367124A1 (en) | 1997-08-01 | 2003-12-03 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| NZ512122A (en) | 1998-11-27 | 2003-12-19 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| ATE444971T1 (de) | 1999-06-09 | 2009-10-15 | Genentech Inc | Zusammensetzungen und verfahren für die tumor- behandlung |
| JP2003525611A (ja) | 2000-03-02 | 2003-09-02 | アムジェン インコーポレーテッド | コルディン様−２分子およびその使用 |
| WO2001092308A2 (en) | 2000-06-01 | 2001-12-06 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| EP1366156A2 (en) | 2000-06-19 | 2003-12-03 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| JP4451059B2 (ja) | 2000-09-01 | 2010-04-14 | ジェネンテック インコーポレイテッド | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| JP4467304B2 (ja) | 2001-12-06 | 2010-05-26 | バイオコントロール システムズ，インコーポレイティド | サンプル収集および試験システム |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| EP1575481A4 (en) | 2002-03-01 | 2010-01-06 | Celltech R & D Inc | PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| WO2004098491A2 (en) | 2002-11-01 | 2004-11-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| FI115753B (fi) | 2002-11-29 | 2005-07-15 | Paloheimo Raija | Menetelmä ja sovitelma kahvijuomien valmistamiseksi |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| PT1608399E (pt) | 2003-03-14 | 2012-04-13 | Ucb Mfg Inc | Complexo de esclerostina e noguina ou cordina, e agentes que modulam a formação do referido complexo |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| US20100028335A1 (en) | 2007-02-02 | 2010-02-04 | Novartis Ag | Compositions and Methods to Treat Bone Related Disorders |
| CN101646457B (zh) | 2007-03-20 | 2013-05-01 | 伊莱利利公司 | 抗硬骨素抗体 |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| EP2209491B1 (en) | 2007-11-02 | 2015-10-28 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
| CN101896201A (zh) | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
-
2006
- 2006-04-25 US US11/410,540 patent/US8003108B2/en active Active
- 2006-04-28 EP EP10014372.6A patent/EP2295448B2/en active Active
- 2006-04-28 DK DK10006930.1T patent/DK2251351T4/da active
- 2006-04-28 HR HRP20170514TT patent/HRP20170514T4/hr unknown
- 2006-04-28 ES ES10014360T patent/ES2901698T3/es active Active
- 2006-04-28 EP EP10014360.1A patent/EP2345668B1/en active Active
- 2006-04-28 CA CA2607276A patent/CA2607276C/en active Active
- 2006-04-28 ES ES10014373T patent/ES2624643T5/es active Active
- 2006-04-28 SI SI200632158T patent/SI2251351T2/sl unknown
- 2006-04-28 ES ES10006930T patent/ES2619709T5/es active Active
- 2006-04-28 FI FIEP10006930.1T patent/FI2251351T4/fi active
- 2006-04-28 MX MX2011003958A patent/MX348432B/es unknown
- 2006-04-28 EP EP06751835A patent/EP1891100A2/en not_active Withdrawn
- 2006-04-28 LT LTEP10014373.4T patent/LT2301961T/lt unknown
- 2006-04-28 FI FIEP10014373.4T patent/FI2301961T4/fi active
- 2006-04-28 HR HRP20170679TT patent/HRP20170679T4/hr unknown
- 2006-04-28 ES ES10014372T patent/ES2620684T5/es active Active
- 2006-04-28 PL PL10014373.4T patent/PL2301961T5/pl unknown
- 2006-04-28 EP EP10014361.9A patent/EP2298800B9/en active Active
- 2006-04-28 PT PT100069301T patent/PT2251351T/pt unknown
- 2006-04-28 PT PT100143734T patent/PT2301961T/pt unknown
- 2006-04-28 EP EP10006930.1A patent/EP2251351B2/en active Active
- 2006-04-28 JP JP2008510081A patent/JP5680823B2/ja active Active
- 2006-04-28 LT LTEP10006930.1T patent/LT2251351T/lt unknown
- 2006-04-28 PL PL10006930.1T patent/PL2251351T5/pl unknown
- 2006-04-28 HU HUE10014373A patent/HUE032092T2/en unknown
- 2006-04-28 WO PCT/US2006/016345 patent/WO2006119062A2/en active Application Filing
- 2006-04-28 ES ES10014361T patent/ES2616985T5/es active Active
- 2006-04-28 SI SI200632170T patent/SI2301961T2/sl unknown
- 2006-04-28 HU HUE10006930A patent/HUE033718T2/en unknown
- 2006-04-28 DK DK10014373.4T patent/DK2301961T4/da active
- 2006-04-28 EP EP10014373.4A patent/EP2301961B9/en active Active
- 2006-04-28 MY MYPI20093533A patent/MY174493A/en unknown
-
2011
- 2011-04-28 US US13/096,263 patent/US8715663B2/en active Active
-
2014
- 2014-02-20 US US14/185,590 patent/US9353174B2/en active Active
- 2014-05-07 JP JP2014095921A patent/JP2014177470A/ja active Pending
-
2015
- 2015-09-30 JP JP2015192869A patent/JP6158268B2/ja active Active
-
2017
- 2017-02-23 JP JP2017031654A patent/JP2017128583A/ja active Pending
- 2017-03-31 CY CY20171100393T patent/CY1118977T1/el unknown
- 2017-05-09 CY CY20171100495T patent/CY1119127T1/el unknown
-
2018
- 2018-08-06 JP JP2018147689A patent/JP6858733B2/ja active Active
-
2020
- 2020-05-07 JP JP2020081948A patent/JP7010994B2/ja active Active
-
2021
- 2021-12-01 JP JP2021195517A patent/JP7361086B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170514T4 (hr) | Epitopi sklerostina | |
| HRP20211904T1 (hr) | Sklerostin vezujuća sredstva | |
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| CN106632674B (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
| CA2682212C (en) | Anti-sclerostin antibodies | |
| RU2504551C2 (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP2022166238A5 (hr) | ||
| BRPI0508716A (pt) | anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal | |
| MX2009010120A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. | |
| HRP20150934T1 (hr) | Djelovanje na abcb5 u terapiji raka | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2007530068A5 (hr) | ||
| WO2007044411A3 (en) | Anti-myostatin antibodies | |
| EA012079B3 (ru) | Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения | |
| CL2008002668A1 (es) | Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp. | |
| RS52357B (en) | BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE | |
| HRP20120606T4 (hr) | Protutijela protiv il-17 | |
| BRPI0210405B8 (pt) | anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão | |
| ATE523523T1 (de) | Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung | |
| NZ712762A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| MX2022005850A (es) | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. | |
| SI2791177T1 (en) | Molecules that bind thrombin antibodies and their use |